利伐沙班与传统抗凝药物在80岁以上静脉血栓栓塞症患者中的有效性与安全性对比

Comparison of efficacy and safety between rivaroxaban and traditional anticoagulants in patients over 80 years old with venous thromboembolism

目的:比较利伐沙班与传统抗凝药物在80岁以上静脉血栓栓塞症患者中的有效性与安全性。方法:回顾性分析45例80岁以上静脉血栓栓塞症患者的临床资料。采用利伐沙班治疗28例(利伐沙班组),传统抗凝药物(低分子肝素联合华法林或单用低分子肝素)治疗17例(传统抗凝组)。比较两组患者治疗12个月内的复发、出血、死亡及总体有效率的差异。结果:两组患者基线资料差异无统计学意义。治疗12个月内,两组复发、出血、血栓相关死亡及抗凝总体有效率差异均无统计学意义。利伐沙班组及其肿瘤患者亚组的全因死亡均低于传统抗凝组(P<0.05)。结论:利伐沙班与传统抗凝药物在80岁以上静脉血栓栓塞症患者中的有效性和安全性可能相似。

Objective:To compare the efficacy and safety between rivaroxaban and traditional anticoagulants in patients over 80 years old with venous thromboembolism.Methods:The clinical data of 45 patients over 80 years old with venous thromboembolism were retrospectively analyzed.Among whom,28 cases were treated with rivaroxaban(rivaroxaban group),and 17 cases were treated with traditional anticoagulants(low-molecular weight heparin combined with warfarin or low-molecular weight heparin alone;traditional anticoagulation group).The differences of recurrence,bleeding events,deaths,and efficiency were compared between the two groups within 12 months of treatment.Results:There was no statistically significant difference in the baseline data of patients between the two groups.Within 12 months of treatment,there was no statistically significant difference in the rates of recurrence,bleeding events,thrombosis-related deaths,and overall effective rate of anticoagulation between the two groups.The all-cause mortality in the rivaroxaban group and subgroup of tumor patients was lower than that in the traditional anticoagulation group(P<0.05).Conclusions:The safety and efficacy of rivaroxaban and traditional anticoagulants may be similar in patients over 80 years old with venous thromboembolism.